Applications of lentiviral vectors for biology and gene therapy of neurological disorders.
Recombinant lentiviral vectors (rLV) are powerful tools for gene transfer to the central nervous system (CNS) and hold great potential as a therapeutic gene therapy strategy for neurological disorders. Recent data indicate that rLVs are suitable for functional studies in the CNS by over expression or knock down of specific proteins. Based on a variety of lentiviruses species, different vector systems have been developed. However, the most commonly used rLV vector is based on the human immunodeficiency virus 1 (HIV-1). Here we describe the use of such vectors to achieve cell-specific transgene expression in the brain. In this setting, rLVs are versatile tools both due to their relatively large cloning capacity and their ability to transduce non-dividing cells. Furthermore, we discuss the preclinical development of gene therapy based on enzyme replacement and/or delivery of neurotrophic factors for neurodegenerative diseases and CNS manifestations of lysosomal storage diseases. Neuroprotective strategies that aim to deliver glial cell line-derived neurotrophic factor and ciliary neurotrophic factor for Parkinson's and Huntington's diseases in particular have been documented with success in appropriate animal models. More recently, rLVs were shown to be suitable to express small interfering RNA for treatment in models of Alzheimer's disease and amyotrophic lateral sclerosis. Finally, we present a review of the use of rLVs to model neurodegenerative diseases. rLVs have proven to be a very versatile tool to create genetic models of both Parkinson's and Huntington's diseases and thus provide possibilities to study complex genetic interactions in otherwise wild-type animals evading the necessity to create transgenic mice. Moreover, the potential of these vectors in the development of gene therapy to treat neurological disorders is considerable, which is supported by the fact that clinical trials using rLVs are underway.
Lundberg
Cecilia
C
Department of Experimental Medical Science, Lund University, BMC D11, 22184, Lund, Sweden.
Björklund
Tomas
T
Carlsson
Thomas
T
Jakobsson
Johan
J
Hantraye
Philippe
P
Déglon
Nicole
N
Kirik
Deniz
D
D000818:Animals; D020934:Ciliary Neurotrophic Factor / Q000378:metabolism; D002986:Clinical Trials as Topic; D005786:Gene Expression Regulation; D005818:Genetic Engineering / Q000379:methods; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000378:metabolism; D006801:Humans; D006816:Huntington Disease / Q000235:genetics / Q000628:therapy; D016086:Lentivirus / Q000235:genetics*; D009414:Nerve Growth Factors / Q000378:metabolism; D009422:Nervous System Diseases / Q000235:genetics* / Q000628:therapy*; D010300:Parkinson Disease / Q000235:genetics / Q000628:therapy; D034622:RNA Interference
D020934:Ciliary Neurotrophic Factor; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors